Derbend Asset Management’s NovoCure NVCR Stock Holding History

Derbend Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,714	Closed	-$354K	–	84
2022 Q1	$354K	Hold	4,714	–	–	0.35%	60
2021 Q4	$354K	Sell	4,714 -894	-16%	-$89.7K	0.35%	59
2021 Q3	$651K	Sell	5,608 -181	-3%	-$27.4K	0.61%	46
2021 Q2	$1.28M	Buy	+5,789	New	+$1.13M	1.2%	28

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Derbend Asset Management's NVCR Position: Q2 2022 in Review

Derbend Asset Management sold out of NovoCure (NVCR) in Q2 2022, closing a stake of 4,714 shares — an estimated $354K sold.

Derbend Asset Management first reported a position in NVCR in Q2 2021 and held it in 4 quarters. The position peaked at $1.28M in Q2 2021. 316 funds tracked by Wall St. Rank hold NVCR as of Q2 2022.

Derbend Asset Management reported no remaining NovoCure position as of Q2 2022 after selling out during the quarter.
Derbend Asset Management sold 4,714 NovoCure shares in Q2 2022, an estimated $354K.
Derbend Asset Management first reported a position in NovoCure in Q2 2021 and held it in 4 quarters.
Derbend Asset Management's NovoCure position peaked at $1.28M in Q2 2021.
316 funds tracked by Wall St. Rank held NovoCure as of Q2 2022.

Based on Derbend Asset Management's 13F filing for Q2 2022, filed 21 Jul 2022.